Globe Newswire (Wed, 26-Aug 9:00 AM ET)
Market Chameleon (Wed, 19-Aug 5:51 AM ET)
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc
Globe Newswire (Wed, 19-Aug 9:00 AM ET)
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Globe Newswire (Fri, 14-Aug 4:05 PM ET)
Globe Newswire (Wed, 12-Aug 9:00 AM ET)
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Globe Newswire (Fri, 7-Aug 9:25 AM ET)
Femasys Regains Compliance with Nasdaq Listing Requirements
Globe Newswire (Wed, 24-Jun 9:00 AM ET)
Market Chameleon (Mon, 3-Nov 5:31 AM ET)
FEMY Jumps 30.32% as New Zealand Grants Regulatory Green Light to FemBloc Non-Surgical Birth Control
Market Chameleon (Mon, 8-Sep 10:28 AM ET)
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Femasys trades on the NASDAQ stock market under the symbol FEMY.
As of September 8, 2026, FEMY stock price declined to $2.71 with 73,431 million shares trading.
FEMY has a beta of 0.19, meaning it tends to be less sensitive to market movements. FEMY has a correlation of 0.00 to the broad based SPY ETF.
FEMY has a market cap of $22.70 million. This is considered a Sub-Micro Cap stock.
Last quarter Femasys reported $756,716 in Revenue and -$1.08 earnings per share. This beat revenue expectation by $26,046 and exceeded earnings estimates by $.32.
In the last 3 years, FEMY traded as high as $95.00 and as low as $2.02.
The top ETF exchange traded funds that FEMY belongs to (by Net Assets): VTI, VXF.
FEMY has underperformed the market in the last year with a price return of -63.2% while the SPY ETF gained +19.4%. FEMY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.1% and -8.4%, respectively, while the SPY returned +1.7% and +0.3%, respectively.
FEMY support price is $2.73 and resistance is $3.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FEMY shares will trade within this expected range on the day.
